Generic Drug 180-Day Exclusivity Reform Proposal Is Cost-Neutral, CBO Says
Executive Summary
Sen. Orrin Hatch (R-Utah) is likely to continue to push for changes in the 180-day generic drug exclusivity provisions in Medicare legislation despite a cost-neutral CBO score on the approach already included in the Senate legislation
You may also be interested in...
Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch
Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)
Apotex Generic Paxil Priced At 7% Discount Following “At Risk” Launch
Apotex is relying on a district court ruling of noninfringement in launching the first generic of GlaxoSmithKline's antidepressant Paxil (paroxetine)
Generic Drug 180-Day Exclusivity Provisions: Hatch Seeks CBO Score
Sen. Orrin Hatch (R-Utah) wants the Congressional Budget Office to help him make the case that 180-day generic drug exclusivity provisions in the Senate and House Medicare bills need revision